The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha Clinic	Alpha Clinic Contact	Trial Sponsor	Disease Indication	Clinical Trial Name	Status of Enrollment	Learn More
UCLA	Kit L Shaw, PhD (310) 267-0584 kshaw@mednet.ucla.edu	Orchard Therapeutics	Severe Combined Immunodeficiency (SCID)	Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency	Active, not recruiting
UCSD	Teresa Rzesiewicz 844-317-7836 alphstemcellclinic@ucsd.edu	Discgenics	Degenerative Disc Disease	Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration	Active, not recruiting
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Viacyte	Diabetes - Type 1	A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus	Active, not recruiting
UCSD		Aivita	Ovarian and Fallopian Tube Carcinoma	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas	Active, not recruiting	Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcino
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Fate Therapeutics	Solid tumors	FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors	Active, not recruiting	FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors
UCSD	Barbara Parker, MD 858-822-6135 baparker@ucsd.edu Rebecca Shatsky, MD 858-657-7000 rshatsky@ucsd.edu	UCSD	Cancer - Breast	Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer	Active, not recruiting
UCSF & UC Davis	Caleb Hwang 415-502-3498 Caleb.hwang@ucsf.edu Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Poseida Therapeutics, Inc.	Multiple Myeloma	Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME)	Active, not recruiting	NCT03288493
UCSF	Cyrus Bascon 510-428-3885 ext 5396 CBascon@mail.cho.org	bluebird bio	Sickle Cell Disease	A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease	Active, not recruiting	NCT02140554
City of Hope	Hormoz Mirshkarlo 626-218-8074 hmirshkarlo@coh.org	Kite Pharma	Cancer - Lymphoma	A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6)	No longer active
City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Leukemia	Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)	No longer active
City of Hope	Cara Nolan 626-256-4673 ext 32341 cnolan@coh.org	Juno Therapeutics	Cancer - Leukemia	Long-Term Follow-up Study for Patients Previously Treated With JCAR015	No longer active
City of Hope	Erminia Massarelli, MD 626-218-9200 emassarelli@coh.org	Atara Bio.	Cancer - Nasopharyngeal Carcinoma	Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)	No longer active
UC Davis	Jane McCluskepy 916-703-9302 jmccluskey@ucdavis.edu	Medeor Therapuetics	Kidney Transplant	Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@hotmail.com	Capricor Therapeutics	COVID	A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19	No longer active	A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in P
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Kite Pharma	Advanced Cancer	A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Atara Bio.	EBV-PTLD	Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Capricor Therapeutics	Muscle - Duchenne Muscular Dystrophy	A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)	No longer active
UC Davis	Jane McCluskey 916-703-9302 jmccluskey@ucdavis.edu	Nohla Therapeutics	Cancer – Leukemia	Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML	No longer active
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	jCyte	Eye - Retinitis Pigmentosa (RP)	Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa	No longer active
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	ImmunoCellular Therapeutics	Cancer - Brain	A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma	No longer active
UCI	UCI Stem Cell Clinic (949) 824-3990 stemcell@uci.edu	SanBio	Stroke	Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke	No longer active
UCLA	Kit L Shaw, PhD (310) 267-0584 kshaw@mednet.ucla.edu	UCLA	Severe Combined Immunodeficiency (SCID)	Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)	No longer active
UCLA	Sarah Larson, MD 310-206-8477 slarson@mednet.ucla.edu	UCLA	Cancer	TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM)	No longer active
UCLA	Maricela Gonzalez (310) 557-3729 mmgonzalez@mednet.ucla.edu	Calimmune	HIV/AIDS	Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection	No longer active
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Asterias Biotherapeutics	Spinal Cord Injury	Dose Escalation Study of AST-OPC1 in Spinal Cord Injury	No longer active
UCSD	UCSD Stem Cell Clinic (844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens	No longer active
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia	No longer active
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	Persimmune, Inc.	Cancer - Blood	Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)	No longer active
UCSD	(844) 317-7836 alphastemcellclinic@ucsd.edu	UCSD	Cancer - Leukemia	Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961	No longer active

Pages

• « first
• ‹ previous
• 1
• 2
• 3

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News